Contact Us
Drug Search Results
More Filters [+]

Lisdexamfetamine

Alternative Names: lisdexamfetamine, vyvanse, lisdexamphetamine, nrp104, elvanse
Latest Update: 2024-07-31
Latest Update Note: News Article

Product Description

Mechanisms of Action: DRI Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Denmark | Dominican Republic | Estonia | Finland | Germany | Hong Kong | Iceland | Ireland | Israel | Japan | Lithuania | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Singapore | South Africa | Spain | Sweden | Switzerland | United Kingdom | United States

Approved Indications: Binge-Eating Disorder | Attention Deficit Disorder with Hyperactivity

Known Adverse Events: Attention Deficit Disorder with Hyperactivity | Abdominal Pain | Dizziness | Pain Unspecified | Insomnia | Anorexia | Constipation | Diarrhea

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lisdexamfetamine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

07/31/2024

News Article

 Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

07/15/2024

News Article

 Eighth Annual Navitus Drug Trend Report Reveals How Plan Sponsors Save on Prescription Drugs Amid Rising Costs and Inflation

07/12/2024

News Article

 Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio

06/27/2024

News Article

 Binge-Eating Disorder Treatment Market size is set to grow by USD 568.7 million from 2024-2028, Increasing prevalence of binge-eating disorder boost the market, Technavio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions